Ke piʻi nei ka nui o ka maʻi prostate i kēlā me kēia makahiki, a ua lilo ia i mea pepehi kanaka nui e pili ana i ke olakino o nā kāne ʻelemakule.I kēia manawa, ua hoʻokumu ʻo Kina i nā maʻamau no ka nānā ʻana i ka maʻi maʻi prostate, akā pono ia e hoʻomau i ka hoʻolaha ʻana i ka hoʻolaha ʻana o ka ʻike screening lehulehu.Ua ʻōlelo ʻo Ye Dingwei, ka hope pelekikena o ka Halemai maʻi maʻi e pili ana i ke Kulanui ʻo Fudan a me ke poʻo o ka ʻoihana urology, i ka ʻaha kūkā no ka holomua ʻana o ka maʻi maʻi prostate hou i mālama ʻia ma Guangzhou e pono mau ana ʻo Kina e hoʻoikaika i kāna kuleana alakaʻi i ka noiʻi lāʻau lapaʻau hou. hoʻomohala i nā hoʻokolohua lapaʻau, i mea e wikiwiki ai i ka hoʻonui ʻana a me ka hoʻokomo ʻana i nā lāʻau lapaʻau hou aʻe a pōmaikaʻi i nā maʻi hou aʻe ma Kina.
ʻO ka maʻi maʻi prostate kahi maʻi maʻi epithelial malignant e kū mai ana i loko o ka prostate a ʻo ia ka maʻi maʻi maʻamau maʻamau i ka ʻōnaehana urogenital kāne.No ka loaʻa ʻole o nā hōʻailona maʻi kūikawā i ka wā mua, kuhi pinepine ʻia e nā kauka a i ʻole nā mea maʻi no ka prostatic hypertrophy a i ʻole hyperplasia, a ʻo ka nui o nā maʻi i hele ʻole e ʻike i ke kauka a loaʻa iā lākou nā hōʻailona metastatic e like me ka ʻeha iwi.ʻO ka hopena, kokoke i ka 70% o nā mea maʻi maʻi maʻi maʻi prostate ma Kina ua holomua a ākea ka maʻi prostate metastatic i ka manawa i ʻike ʻia, me ka maikaʻi ʻole o ka mālama ʻana a me ka wānana.Eia kekahi, piʻi ka nui o ka maʻi maʻi prostate i ka makahiki, e piʻi wikiwiki ana ma hope o ka makahiki 50, a hiki i ka piʻi o ka helu a me ka make o 85 mau makahiki i ka piko.Ma lalo o ke kumu o ka hohonu o ka ʻelemakule ma Kina, e piʻi aʻe ka nui o nā poʻe me ka maʻi prostate ma Kina.
Ua ʻōlelo ʻo Ye Dingwei, ua ʻoi aku ka nui o ka piʻi ʻana o ka maʻi prostate ma Kina ma mua o nā maʻi maʻi paʻa ʻē aʻe, a ke piʻi nui nei ka make.I ka manawa like, ʻoi aku ka liʻiliʻi o ka ola ola ʻelima mau makahiki o ka maʻi maʻi prostate ma Kina ma mua o 70%, ʻoiai ma ʻEulopa a me ʻAmelika Hui Pū ʻIa, ʻoi aku hoʻi ʻo ʻAmelika Hui Pū ʻIa, kokoke i 100% ka helu ola ʻelima mau makahiki."ʻO ke kumu nui o kēia kūlana ʻo ia ka nāwaliwali o ka ʻike ʻana i ka nānā ʻana o ka ʻāina ma Kina, a ʻaʻohe manaʻo i ka ʻike e pono i nā hui kiʻekiʻe ke hana i ka screening PSA i kēlā me kēia ʻelua makahiki;a ʻaʻole i loaʻa i kekahi mau maʻi ka maʻi maʻamau a me ka mālama ʻana, a pono e hoʻomaikaʻi ʻia ka ʻōnaehana holoʻokoʻa holoʻokoʻa o ka maʻi prostate ma Kina.
E like me ka hapa nui o nā maʻi maʻi maʻi, hiki ke hoʻonui i ka nui o ke ola ʻana, ka ʻike mua ʻana, ka ʻike a me ka mālama ʻana i ka maʻi maʻi prostate.Ua ʻōlelo ʻo Zeng Hao, ka lālā o ka Pūʻulu ʻImi ʻōpio a me ke Kakauolelo Nui o ka lālā Urology o ka Hui Lapaʻau Kina, ua pili nui ka poʻe ʻEulopa a me ʻAmelika i ka pale ʻana a me ka mālama ʻana i ka maʻi maʻi prostate, a ʻo ka nui o ka nānā ʻana i ka maʻi prostate. kiʻekiʻe, kahi e hiki ai i nā poʻe maʻi me ka maʻi maʻi prostate mua ke loaʻa i nā manawa lapaʻau maikaʻi, ʻoiai ʻo ka lehulehu o Kina he haʻahaʻa haʻahaʻa i ka nānā ʻana i nā maʻi, a ʻo ka hapa nui o nā mea maʻi he maʻi maʻi kūloko a ākea ka maʻi prostate metastatic i ka manawa i ʻike ʻia.
"Aia mau ka hakahaka nui ma waena o ka poʻe maʻi maʻi maʻi prostate o Kina a me ʻEulopa a me ʻAmelika Hui Pū ʻIa mai ka hoʻomaka ʻana i ka maʻi maʻi a hiki i ka mālama ʻana i ka prognosis.No laila, he lōʻihi ka hele ʻana o ka pale ʻana a me ka mālama ʻana i ka maʻi prostate o Kina," wahi a Zeng Hao.
Pehea e hoʻololi ai i ke kūlana quo?Ua ʻōlelo ʻo Ye Dingwei ʻo ka mea mua e hoʻolaha i ka ʻike o ka nānā mua ʻana.Pono e nānā ʻia nā maʻi prostate ma mua o 50 mau makahiki me ka pilikia nui no ka prostate specific antigen (PSA) i kēlā me kēia ʻelua makahiki.ʻO ka lua, ʻo ka mālama ʻana i ka maʻi maʻi prostate e uku nui i ka mālama ʻana i ka pololei a me ka manaʻo holoʻokoʻa.ʻO ke kolu, i ka mālama ʻana, pono mākou e hoʻolohe i ka mālama ʻana i nā multidisciplinary (MDT) no nā poʻe maʻi me ka maʻi prostate ma waena a me nā pae hope.Ma o ka hui pū ʻana o nā ʻano like ʻole i luna, hiki ke hoʻomaikaʻi nui ʻia ka nui o ke ola o ka maʻi prostate ma Kina i ka wā e hiki mai ana.
"He lōʻihi kā mākou e hele ai i ka hoʻomaikaʻi ʻana i ka helu maʻi mua a me ka helu pololei o ka ʻike."Ua ʻōlelo ʻo Zeng Hao, ʻo ka paʻakikī nui o ka hoʻomaikaʻi ʻana i ka maʻi maʻi mua a me ka hoʻomaʻamaʻa mua ʻana, ʻo ia i ka hana lapaʻau, ʻo ka waiwai o nā mea hōʻailona tumo he mea kuhikuhi kuhikuhi nui wale nō, a pono e hui pū ʻia ka maʻi o ka maʻi me ke kiʻi a i ʻole ka biopsy puncture no ka piha. ka maʻi maʻi, akā ʻo ka makahiki waena o nā maʻi maʻi prostate ma waena o 67 a me 70 mau makahiki, ʻO kēia ʻano o nā poʻe maʻi ʻelemakule he haʻahaʻa ka ʻae ʻana i ka biopsy puncture.
I kēia manawa, ʻo nā ʻano lapaʻau maʻamau no ka maʻi maʻi prostate e pili ana i ka ʻokiʻoki, radiotherapy, chemotherapy a me ka endocrine therapy, ma waena o ka endocrine therapy ke ʻano nui o ka mālama ʻana no ka maʻi prostate.
Ua ʻōlelo ʻo Ye Dingwei, ʻo nā hopena o ASCO-GU i hoʻokuʻu ʻia i kēia makahiki, ua hōʻike ʻia ka hui pū ʻana o ka PARP inhibitor Talazoparib a me enzalutamide i loaʻa i nā hopena maikaʻi i ka hoʻāʻo ʻana o ka lāʻau lapaʻau III, a ua hoʻomaikaʻi maikaʻi ʻia ka manawa ola holoʻokoʻa. ʻoi aku ka maikaʻi o nā hopena i manaʻo ʻia, me ka manaʻolana e hoʻomaikaʻi i ka maikaʻi holoʻokoʻa o ke ola o nā poʻe maʻi me ka metastatic castration resistant prostate cancer i ka wā e hiki mai ana.
"Aia mau ka mākeke a me nā pono lapaʻau ʻole i ka hoʻokomo ʻana i nā lāʻau lapaʻau hou i ko mākou ʻāina."Ua ʻōlelo ʻo Ye Dingwei ua manaʻo ʻo ia e hoʻolalelale i ka hoʻokomo ʻana i nā lāʻau hou, a ua manaʻolana hoʻi e hiki i ka hui lapaʻau Kina ke komo i nā hoʻokolohua lapaʻau o nā lāʻau lapaʻau honua, e mālama i ka pae like me ka noiʻi a me ka hoʻomohala ʻana a me ka mākeke, a hana pū e lawe mai i nā mea hou aku. nā koho lapaʻau hou no ka poʻe maʻi, hoʻomaikaʻi i ka helu maʻi mua a me ke ola holoʻokoʻa.
ʻO JinDun Medicalloaʻa i ka hui noiʻi ʻepekema lōʻihi a me ka grafting ʻenehana me nā kulanui Kina.Me nā waiwai lapaʻau waiwai o Jiangsu, loaʻa iā ia nā pilina kālepa lōʻihi me India, Asia Hema, South Korea, Iapana a me nā mākeke ʻē aʻe.Hāʻawi pū ia i nā lawelawe mākeke a me ke kūʻai aku i ke kaʻina holoʻokoʻa mai waena a hiki i ka huahana huahana API.E hoʻohana i nā kumuwaiwai i hōʻiliʻili ʻia o Yangshi Chemical i loko o ka kemika fluorine e hoʻolako i nā lawelawe hana hana kemika kūikawā no nā hoa.Hāʻawi i nā lawelawe noiʻi kaʻina hana a me ka haumia i nā mea kūʻai aku.
Ke koi nei ʻo JinDun Medical i ka hoʻokumu ʻana i kahi hui me nā moeʻuhane, hana i nā huahana me ka hanohano, meticulous, rigorous, a hele i nā mea a pau e lilo i hoa hilinaʻi a me ka hoaaloha o nā mea kūʻai aku! ʻoihanahana lāʻau lapaʻau maʻamau(CMO) a me nā mea lawelawe R&D lāʻau lapaʻau maʻamau a me ka hana (CDMO).
Ka manawa hoʻouna: Mar-20-2023